Table 1.

Summary of sirtuin-targeting compounds and their effects in immune cell populations.

Compound	Function	Role in Immune Cells	Species Described
Resveratrol	Sirtuin activator	Increases LSK frequency ex vivo [35]	Mouse
		Limits T cell proliferation in vivo and ex vivo [40]	Mouse
		Enhances SIRT1 deacetylase activity towards c-Jun in T cells [40]	Mouse
		Reduces Th17 differentiation ex vivo and in vivo [41]	Human and mouse
		Enhances SIRT1 deacetylase activity on STAT3 in Th17 cells [41]	Human and mouse
Nicotinamide	Sirtuin inhibitor	Decreases LSK frequency ex vivo [35]	Mouse
		Promotes LSK differentiation into granulocytes ex vivo [35]	Mouse
		Limits macrophage self-renewal through cell cycle control [42]	Mouse
		Increases Treg frequencies and activity ex vivo [43,44]	Human and mouse
		Increases FOXP3 acetylation and protein stability in Treg cells [43]	Human and mouse
Metformin & SRT-1720	SIRT1 agonists	Reduces Th17 differentiation ex vivo and in vivo [45]	Human and mouse
		Enhances SIRT1 deacetylase activity on STAT3 in Th17 cells [41]	Human and mouse
		Reduces AID expression and impairs CSR in B cells (SRT-1720 only) [46]	Mouse
Sirtinol	SIRT1 antagonist	Reduces LSK and LT-HSC frequency and numbers in vivo [35]	Mouse
		Diminishes HSC repopulation capacity [39]	Mouse
Cambinol	SIRT1/2 inhibitor	Promotes a proinflammatory phenotype in macrophages ex vivo [47]	Human
S6	SIRT6 inhibitor	Limits the differentiation of monocytes to dendritic cells ex vivo [48]	Human